retatrutide weight loss retatrutide clinical trial Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a retatrutide weight loss clinical trials

PubMed Glucagon-like receptor agonists and next-generation incretin-based medications Current review for incretin-based obesity medications and cardiometabolic effects

If you're ready to ensure your research is built on a foundation of purity and precision, you can Get Started Today by exploring our lab-verified peptides, all of which are available on our Shop All Peptides page

Merki, E

Based on Phase 2 trial protocols, the standard approach looks like this: Weeks 1 to 4: 1 mg once weekly Weeks 5 to 8: 2 mg once weekly Weeks 9 to 12: 4 mg once weekly Weeks 13 to 16: 8 mg once weekly Weeks 17 onward: 12 mg once weekly (if tolerated) That is a minimum 16 to 20 week ramp-up to reach the maximum dose, compared to a similar timeline for Ozempic